当前位置: 首页 > 期刊 > 《上海医药》 > 2013年第1期
编号:12335160
噻唑烷二酮类药物抑制肿瘤细胞作用研究进展(4)
http://www.100md.com 2013年1月1日 《上海医药》 2013年第1期
     [13] Ohta T, Elnemr A, Yamamoto M, et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-γ ligand, modulates the E-cadherin/h-catenin system in a human pancreatic cancer cell line, BxPC-3[J]. Int J Oncol, 2002, 21(1): 37-42.

    [14] Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer[J]. Cancer Res, 2000, 60(4): 1129-1138.

    [15] Huang JW, Shiau CW, Yang YT, et al. Peroxisome proliferator-activated receptor γ-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells[J]. Mol Pharmacol, 2005, 67(4): 1342-1348.

    [16] Chen F, Harrison LE. Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation[J]. Cell Signal, 2005, 17(7): 809-816.

    [17] Chen F, Kim E, Wang CC, et al. Ciglitazone-induced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway[J]. Cell Signal, 2005, 17(12): 1572-1577.

    [18] Kim Y, Suh N, Sporn M, et al. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis[J]. J Biol Chem, 2002, 277(25): 22320-22329.

    (收稿日期:2012-09-05)

    , 百拇医药(尤文 张杰)
上一页1 2 3 4